Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.

In our cohort, no significant association was found between the median HRD score and BRCA mutational status (despite a clear trend towards higher HRD scores in BRCA 1/2 mutated tumors: respectively, 50.6 for patients with BRCA 1/2 mutation and 26.3 for patients with WT status, p -value = 0.17) in the whole cohort, or in each BC subtype (Fig. 1a ).

also in 19,460 other papers

However, these differences did not reach statistical significance: p = 1 (for BRCA mutated vs BRCA WT HRD-high), p = 0.15 (for BRCA -mutated vs BRCA WT HRD-low and for the comparison between WT HRD-high and WT HRD-low) (Fig. 2c ).

also in 111,027 other papers